“…In addition, only patients with clear-cell histology were eligible for the study [8]. Although sunitinib has been universally prescribed to patients with mRCC, few studies have examined the efficacy and safety of this agent in daily clinical practice, especially in patients of Asian ethnicity [12][13][14][15]. Here, we assessed the efficacy and safety of sunitinib in Japanese patients with mRCC in general clinical practice.…”